Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This Open Label Extension study will enable eligible patients with Paroxysmal
Supraventricular Tachycardia (PSVT) who have previously participated in a Milestone
Pharmaceutical clinical trial of etripamil for PSVT where they received etripamil Nasal Spray
(NS) during a perceived PSVT episode, and experienced no significant safety issues during
participation, to continue treatment with etripamil NS during the Phase 3 program completion.
This study will be conducted by Investigators who previously participated in a Milestone
Pharmaceuticals clinical trials and are trained on the use of etripamil NS.